PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors
Abstract
PAX8 is a prototype lineage-survival oncogene in epithelial ovarian cancer. However, neither its underlying pro-tumorigenic mechanisms nor potential therapeutic implications have been adequately elucidated. Here, we identified an ovarian lineage-specific PAX8 regulon using modified cancer outlier profile analysis, in which PAX8-FGF18 axis was responsible for promoting cell migration in an autocrine fashion. An image-based drug screen pinpointed that PAX8 expression was potently inhibited by small-molecules against histone deacetylases (HDACs). Mechanistically, HDAC blockade altered histone H3K27 acetylation occupancies and perturbed the super-enhancer topology associated with PAX8 gene locus, resulting in epigenetic downregulation of PAX8 transcripts and related targets. HDAC antagonists efficaciously suppressed ovarian tumor growth and spreading as single agents, and exerted synergistic effects in combination with standard chemotherapy. These findings provide mechanistic and therapeutic insights for PAX8-addicted ovarian cancer. More generally, our analytic and experimental approach represents an expandible paradigm for identifying and targeting lineage-survival oncogenes in diverse human malignancies.
Data availability
The sequencing data have been deposited in NCBI SRA database(http://www.ncbi.nlm.nih.gov/sra/) under the accession number SRP153266.
-
RNAseq of ovarian cancer cell lines: HDAC inhibitors,sgPAX8 treatmentNCBI Sequence Read Archive, SRP153266.
Article and author information
Author details
Funding
National Natural Science Foundation of China (81472537)
- Guanglei Zhuang
Shanghai Municipal Commission of Health and Family Planning (20174Y0043)
- Mei-Chun Cai
Program of Shanghai Hospital Development Center (16CR2001A)
- Wen Di
Shanghai Jiao Tong University School of Medicine (YG2016MS51)
- Xia Yin
The State Key Laboratory of Oncogenes and Related Genes (SB17-06)
- Mei-Chun Cai
Shanghai Sailing Program (18YF1413200)
- Pengfei Ma
National Key R&D Program of China (2016YFC1302900)
- Wen Di
Science and Technology Commission of Shanghai Municipality (18441904800)
- Wen Di
The Shanghai Institutions of Higher Learning (Eastern Scholar)
- Guanglei Zhuang
National Natural Science Foundation of China (81672714)
- Guanglei Zhuang
National Natural Science Foundation of China (81772770)
- Wen Di
National Natural Science Foundation of China (81802584)
- Meiying Zhang
National Natural Science Foundation of China (81802734)
- Pengfei Ma
National Natural Science Foundation of China (81802809)
- Mei-Chun Cai
Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313)
- Guanglei Zhuang
Shanghai Rising-Star Program (16QA1403600)
- Guanglei Zhuang
Shanghai Municipal Commission of Health and Family Planning (2017ZZ02016,ZY(2018-2020)-FWTX-3006)
- Wen Di
Science and Technology Commission of Shanghai Municipality (16140904401)
- Xia Yin
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Wilbert Zwart, Netherlands Cancer Institute, Netherlands
Ethics
Animal experimentation: The institutional animal care and use committee of Ren Ji Hospital approved all animal protocols (permit-number: m20170205) and all animal experiments were in accordance with Ren Ji Hospital policies on the care, welfare, and treatment of laboratory animals.
Version history
- Received: December 11, 2018
- Accepted: May 2, 2019
- Accepted Manuscript published: May 3, 2019 (version 1)
- Version of Record published: May 23, 2019 (version 2)
Copyright
© 2019, Shi et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,005
- views
-
- 526
- downloads
-
- 33
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Genetics and Genomics
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
-
- Cancer Biology
- Cell Biology
Rapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of proteasome inhibitors is upregulated by the transcription factor Nrf1 (NFE2L1), which is activated by a DDI2 protease. Here, we demonstrate that the recovery of proteasome activity is DDI2-independent and occurs before transcription of proteasomal genes is upregulated but requires protein translation. Thus, mammalian cells possess an additional DDI2 and transcription-independent pathway for the rapid recovery of proteasome activity after proteasome inhibition.